Coy et al.

Serial No. : Filed :

10/712,081 November 13, 2003

Page

3

COMPLETE LISTING OF ALL CLAIMS, WITH MARKINGS AND STATUS IDENTIFIERS (Amendments are illustrated by showing deletions by strikethrough or by double brackets for deletions of five or fewer characters and additions by underlining)

Claims 1-17 (canceled)

Claim 18 (currently amended): A compound of claim 2, the formula:

$$\frac{\underline{R_1}}{\Delta} \frac{\Delta^{1}-D-Cys-A^{3}-D-Trp-Lys-A^{6}-Cys-A^{8}-R_{\underline{3}}}{\angle}$$

$$\underline{R_2}$$

wherein

A¹ is a D- or L-isomer of an aromatic amino acid or is deleted;

A³ is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa or an aliphatic amino acid;

A⁸ is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid or an aliphatic amino acid;

each of R₁ and R₂, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E₁SO₂ or E₁CO wherein E₁, is aryl, aryl lower alkyl, heterocycle or heterocycle lower alky and said substituent is halo, lower alkyl, hydroxy, halo lower alkyl or hydroxy lower alkyl; and

Coy et al.

Serial No. :

10/712,081

Filed Page November 13, 2003

 R_3 , together with the carbonyl group of A^8 attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

provided that a disulfide bond links the sidechains of A^2 and A^7 and

further provided that if A^1 is D-Phe or p-NO₂-Phe, A^3 is Phe or Tyr and A^6 is Thr or Val, then A^8 is B-Nal.

19 (currently amended): A compound of claim 18, wherein A is the D- or L-isomer of ß-Nal, o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, PX Phe p-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO,), m-X-Phe (where wherein X is H, OH, CH,, halo, OCH,, NH,, CN, or NO,) F.-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A is S-Nal, o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, p-X-Phe (where wherein X is H, OH, CH,, halo, OCH,, NH,, CN, or NO₂+, m-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, F,-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, S-Ala, Gaba, or Val; and A is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO,), o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO,), m-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or $N0_2$, Igl, Tyr(Bzl), or ß-Nal.

Coy et al.

Serial No. : Filed : 10/712,081

November 13, 2003

Page

5

20 (original): A compound of claim 19, wherein A^1 is the D- or L-isomer of ß-Nal, Phe, p-F-Phe, Trp, p-Cl-Phe, or p-CN-Phe; A^3 is Tyr, Tyr (I), or Pal; A^6 is Val, Tle, Nle, Ile, or Leu; A^8 is p-F-Phe, ß-Nal, Tyr, Dip, p-Cl-Phe, Igl, or p-CN-Phe; R_1 is H, CH₃CO, 4-(2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1-piperizineethanesulfonyl; R_2 is H, and R_3 , together with the carboxy group of A^8 attached thereto, are reduced to form H or CH₃OH.

- 21 (original): A compound of claim 20, wherein A is Pal.
- 22 (currently amended): A compound of claim 19, of the formula:

 H_2 -R-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-L2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

- (H) (CH₃CO) -ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl) -3-hydroxy) propylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;
- H₂[[,]]-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

Coy et al.

Serial No.

10/712,081

November 13, 2003

Filed Page

(H) (CH₃CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-&-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-<math>(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

 H_2 -R-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys- $(2R, 3R-(\frac{2hydroxymethyl}{2-hydroxymethyl})$ -3-hydroxy) propylamide;

(H) (CH₃CO) -ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-<u>(</u>2R, 3R-(2hydroxymethyl <u>2-hydroxymethyl</u>)-3-hydroxy)propylamide;

- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)--3hydroxymethyl 3-hydroxymethyl)propylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

 H_2 - \Re -Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

- (H) (CH₃CO) -ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl) -3-hydroxy) propylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

Coy et al.

Serial No. :

10/712,081

Filed

Page

.

November 13, 2003

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

 H_2 -Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3hydroxy 3-hydroxy)propylamide;

H₂-Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2hydroxymethyl 2-hydroxymethyl)-3-hydroxy) propylamide;

H(CH₃CO)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2hydroxymethyl 2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-

D-Trp-Lys-Val-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2hydroxymethyl 2hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed Page

•

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-DTrp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

H₂-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H) (CH₃CO) Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-<u>(</u>2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

(H)(4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-

 $\label{eq:decomposition} D-Trp-Lys-Thr-Cys-\underline{(}2R,3R-(2-hydroxymethy1)-3-hydroxy)propylamide;$

H,-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

- (H) (CH₃CO)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2naphthyl 2-naphthyl) ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

 $\label{eq:H2-R-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;} \\ H_2-\text{\mathbb{R}-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;} \\$

(H) (CH₃CO)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2naphthyl 2-naphthyl) ethylamide;

(H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

Coy et al.

Serial No. :

10/712,081

Filed Page November 13, 2003

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-8Nal 8-

<u>Nal-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;</u>

H,-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

- (H) (CH₃CO) S-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R- (2naphthyl 2-naphthyl) ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H,-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

- (H) (CH₃CO) -ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R- (2naphthyl 2-naphthyl) ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-

naphthyl)ethylamide;

- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl) Phe-D-Cys-Tyr-D-Trp-Lys-Val-Cys-2R-(2-naphthyl) ethylamide;

 H_2 -Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed Page

10

(H) (CH₃CO) Phe-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2naphthyl <u>2-naphthyl</u>) ethylamide;

- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Val-Cys-2R-(2-naphthyl)ethylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

(H) (CH₃CO) Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-

naphthyl)ethylamide;

- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Tyr-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H,-Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthy1)ethylamide;

- (H) (CH₃CO) Phe-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2naphthyl <u>2-naphthyl</u>) ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;
- (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)Phe-D-Cys-Pal-D-Trp-Lys-Thr-Cys-2R-(2-naphthyl)ethylamide;

H,-ß-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

H₂-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-2R-(2-naphthyl)ethylamide;

 H_2 -R-Nal-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy) propylamide; or

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed

11

Page

H,-Phe-D-Cys-Tyr-D-Trp-Lys-Abu-Cys-(2R, 3R-(2-hydroxymethyl)-3-hydroxy)propylamide;

or a pharmaceutically acceptable salt thereof.

23 (currently amended): A compound of claim 1, the formula:

$$\frac{R_{1}}{\Delta} \frac{\Delta^{1}-A^{2}-A^{3}-D-Trp-Lys-A^{6}-A^{7}-A^{8}-R_{3}}{\angle}$$

$$\frac{R_{2}}{\Delta}$$

wherein

A is a D- or L-isomer of an aromatic amino acid, or is deleted;

[[A,]] \underline{A}^2 is a D-aromatic amino acid or a D-aliphatic amino acid,

A³ is an aromatic amino acid;

A⁶ is Thr, Thr(Bzl), Gly, Ser, an Eaa, or an aliphatic amino acid;

[[A₁]] \underline{A}^{7} is an aromatic amino acid or an aliphatic amino acid, and A is D trp;

A is a D- or L-isomer selected from the group consisting of Thr, Ser, an aromatic amino acid, or an aliphatic amino acid;

each of R, and R,, is, independently, H or substituted or unsubstituted lower alkyl, aryl, aryl lower alkyl, heterocycle, heterocycle lower alkyl, E,SO, or E,CO wherein E,, is aryl, aryl lower alkyl, heterocycle, or heterocycle lower alky and said

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed Page

12

substituent is halo, lower alkyl, hydroxy, halo lower alkyl, or hydroxy lower alkyl; and

R₂ is OH, NH₂, C₁₋₁₂ alkoxy, or NH-Y-CH₂-Z, wherein Y is a C₁₋₁₂ hydrocarbon moiety and Z is H; OH, CO₂H, or CONH₂, or R₃, together with the carbonyl group of A⁸ attached thereto, are reduced to form H, lower alkyl, or hydroxy lower alkyl;

provided if A² is D-Cys or D-Pen and A⁷ is Cys or Pen, then a disulfide bond links the sidechains of A² and A⁷, and

further provided that if A^1 is D-Phe or p-NO₂-Phe, A^2 is D-Cys, A^3 is Phe or Tyr, A^6 is Thr or Val and A^7 is Cys, then A^8 is 8-Nal.

24 (currently amended): A compound of claim 23, wherein A_{1} is an L- amino acid and A_{2} \underline{A}^{2} is a D-aromatic amino acid.

25 (currently amended): A compound of claim 24, wherein each of A₁ A¹, A₃ A³, and A₄ A⁷, is, independently, is ß-Nal, o-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂), p-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN or NO₂), m-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂), F₅-Phe, Trp, Dip, 2-Pal, Tyr(Bzl), His, Igl, Tyr(I), Bta, Bip, Npa, or Pal; A² is D-ß-Nal, D-o-X-Phe (where wherein X is H, OH CH₃, halo, OCH₃, NH₂, CN, or NO₂), D-p-X-Phe (where wherein X is H, OH₄ CH₃, halo, OCH₃, NH₂, CN, or NO₂), D-m-X-Phe (where wherein X is H, OH₄ CH₃, halo, OCH₃, NH₂, CN, or NO₂), O-m-X-Phe (where wherein X is H, OH₄ CH₃, halo, OCH₃, NH₂, CN, or NO₂),

Coy et al.

Serial No. :

10/712,081

November 13, 2003

Filed Page

13

D-F₅-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), DBta D-Bta, D-Bip, D-Npa, or D-Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, ß-Ala, Gaba, or Val; and A⁸ is the D- or L-isomer of Thr, Dip, F₅-Phe, p-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂+, o-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂+, m-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂+, Igl, Tyr (Bzl), or ß-Nal.

26 (currently amended): A compound of claim 25, wherein A¹ is ß-Nal or Phe, A² is D-Cpa or D-Phe; A³ is Phe or Tyr; A⁶ is Abu, Thr, or Val; A⁷ is Phe; and A⁸ is Thr; R₁ is H, CH₃CO, 4-(2hydroxyethyl 2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2-hydroxyethyl)-1piperizineethanesulfonyl 1-piperizineethanesulfonyl; R₂ is H; and R₃ is NH₂.

27 (currently amended): A compound of claim 25 of the formula:

H,-Phe-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;

H,-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;

H₂-Phe-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

 H_2 -\$-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-N H_2 ;

- (H) (CH_3CO) -A-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;
- (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-DCpa <u>D-Cpa</u>-Tyr-D-Trp-Lys-Val-Phe-Thr-NH₂;

Coy et al.

Serial No.

10/712,081

-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH,; or

Filed

November 13, 2003

Page

14

```
(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;
     H,-ß-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (CH,CO) - \( \text{S-Nal-D-Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH} \);
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-D-Cpa-Pal-
D-Trp-Lys-Val-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Pal-D-Trp-Lys-Val-Phe-Thr-NH,;
     H,-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH;
      (H) (CH,CO) - \( \mathbb{S} - \text{Nal-D-Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH} \);
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-<del>DCpa</del> <u>D-Cpa</u>
-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;
     H<sub>2</sub>-S-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (CH<sub>3</sub>CO) - R-Nal-D-Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH<sub>3</sub>;
      (H) (4-(2-hydroxyethyl)-1-piperazinylacetyl)-$\mathbb{G}$-Nal-D-Cpa-Pal-
D-Trp-Lys-Thr-Phe-Thr-NH,;
      (H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-ß-Nal-D-
Cpa-Pal-D-Trp-Lys-Thr-Phe-Thr-NH,;
     H,-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH;
      (H) (CH,CO) - \( \text{S-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-\text{S-Nal-NH}_; } \)
      (H)(4-(2-hydroxyethyl)-1-piperazinylacetyl)-ß-Nal-<del>DCpa</del> D-Cpa
```

Coy et al.

Serial No. :

10/712,081 November 13, 2003

Filed Page

15

(H) (4-(2-hydroxyethyl)-1-piperizineethanesulfonyl)-\$Nal <u>\$B-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-\$-Nal-NH</u>;

 H_2 -R-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-R-Nal-NH $_2$ [[-]]; or H_2 -R-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH $_2$; or a pharmaceutically acceptable salt thereof.

28 (original): A compound of claim 23, wherein A^1 is a D-amino acid and A^2 is a D-aromatic amino acid.

29 (currently amended): A compound of claim 28, wherein each of A1 and A2, is, independently, is D-G-Nal, D-o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO,+, D-p-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO₂+, D-m-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO,+, D-F₅-Phe, D-Trp, D-Dip, D-2-Pal, D-Tyr(Bzl), D-His, D-Igl, D-Tyr(I), D-Bta, D-Bip, D-Npa, or D-Pal; each of A3 and A', is, independently, is S-Nal, o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, p-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, m-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO, F,-Phe, Trp, Dip, 2-Pal, His, Igl, Tyr(I), Bta, Bip, Npa, Tyr(Bzl), or Pal; A⁶ is Thr, Ser, Tle, Thr(Bzl), Abu, Ala, Ile, Leu, Gly, Nle, S-Ala, Gaba, or Val; and A^8 is the D- or L-isomer of Thr, Dip, F_5 -Phe, p-XPhe p-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH, CN, or NO₂+, o-X-Phe (where wherein X is H, OH, CH, halo, OCH, NH,

Coy et al.

Serial No.

10/712,081

November 13, 2003

Filed Page

16

CN, or NO₂+, m-X-Phe (where wherein X is H, OH, CH₃, halo, OCH₃, NH₂, CN, or NO₂+, Igl, Tyr(Bzl), or ß-Nal.

30 (currently amended): A compound of claim 29, wherein A¹ is D-ß-Nal or D-Phe; A² is D-Cpa or D-Phe; A³ is Phe or Tyr; A⁶ is Thr or Val; A⁷ is Phe; and A⁸ is Thr; R₁ is H, CH₃CO, 4-(2hydroxyethyl 2-hydroxyethyl)-1-piperazinylacetyl, or 4-(2hydroxyethyl)-1-piperizineethanesulfonyl 1-

 $\underline{\text{piperizineethanesulfonyl}}; \ R_{2} \ \text{is H; and R, is NH}_{2}.$

31 (currently amended): A compound of claim 29 of the formula:

H₂-D-S-Nal-D-Cpa-Phe-D-Trp-Lys-Val-Phe-Thr-NH₂;

H,-D-S-Nal-D-Phe-Tyr-D-Trp-Lys-Thr-Phe-Thr-NH,;

H₂-D-Phe-D-Phe-Tyr-D-Trp-Lys-Val-Phe-Thr-NH,;

H,-D-&-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-Thr-NH; or

H₂-D-ß-Nal-D-Cpa-Tyr-D-Trp-Lys-Val-Phe-ß-Nal-NH₂; or a pharmaceutically acceptable salt thereof.

32 (new): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

33 (new): A method of promoting the release of insuling in a subject in need thereof, which comprises administering to

Coy et al.

Serial No.

10/712,081 November 13, 2003

Filed Page

17

said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

34 (new): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

35 (new): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

36 (new): A method of imaging cells having somatostatin receptors which comprises administering to said subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 18 having Tyr(I).

37 (new): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 18 or a pharmaceutically acceptable salt thereof.

38 (new): A method of promoting the release of growth hormone in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

Coy et al.

Serial No. :

10/712,081

Filed Page November 13, 2003

39 (new): A method of promoting the release of insulin in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

40 (new): A method of enhancing wound healing in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable sailt thereof.

41 (new): A method of promoting angiogenesis in a subject in need thereof, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.

42 (new): A method of imaging cells having somatostatin receptors which comprises administering to said subject an effective amount of a compound or a pharmaceutically acceptable salt thereof according to claim 23 having Tyr(I).

43 (new): A method of eliciting an antagonist effect from a somatostatin receptor in a subject, which comprises administering to said subject an effective amount of a compound according to claim 23 or a pharmaceutically acceptable salt thereof.